Laurus Labs Announces Q1 FY26 Results: Revenues at ₹ 1,570 Cr; EBITDA at ₹ 389 Cr, 24.8% margins
Laurus Labs, a leading research and development driven pharmaceutical and biotech company in India, has announced its Q1 FY26 results. The company reported revenues of ₹ 1,570 Cr, a 31% growth compared to Q1 FY25. The EBITDA stood at ₹ 389 Cr, representing a 127% growth and a margin of 24.8%. The net profit was ₹ 163 Cr, a 1154% growth. The company's CDMO business reported revenues of ₹ 493 Cr, a 130% growth, driven by several mid-to-late stage NCE deliveries and ramp up from new manufacturing assets. The generics business reported revenues of ₹ 1,048 Cr, a 12% growth. The company has commenced construction of new facilities for CDMO, Generics, and FDF. The company remains confident in its strategic direction and commitment as the source of sustainable value creation.
Key Highlights
- Delivered strong performance in Q1; Revenues ₹ 1,570 Cr and +31% revenue growth
- Sustained CDMO momentum, expanding collaboration in complex API and supported by growth in Generics
- 389 Cr EBITDA with a margin of 24.8%, improvement is due to ramp up in CDMO projects and Operating leverage
- Commenced construction of new Gene/ADC facility in Hyderabad, and Microbial fermentation facility in Vizag
- Generics business reported revenues of ₹ 1,048 Cr, during Q1FY26, increased by 12%